Viracta Therapeutics (VIRX) Total Debt to Capital

Viracta Therapeutics - graphic logo of issuer VIRX

Viracta Therapeutics (VIRX) develops drugs for viral-induced oncological diseases, demonstrating high resilience to market cycles thanks to its patent portfolio. However, the company faces intense pressure from pharmaceutical industry behemoths. This chart of the separate_debt_total_eq metric is fixed at 0.00. The business currently relies on the completion of final trials for targeted lymphoma treatments, awaiting official approvals for monetization.

Viracta Therapeutics Inc. (VIRX): Debt to Equity Ratio from 07/04/2022 to 02/16/2025

Metric breakdowns and analytics for Viracta Therapeutics, Inc. (VIRX)

- share price and consensus valuation forecast:
Stock Price Viracta Therapeutics Inc.|VIRX - Consensus Target
- market capitalization details:
Market Capitalization Viracta Therapeutics|VIRX - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Viracta Therapeutics|VIRX - Accounting Capitalization|Market Capitalization to Book Value Ratio viracta.com|VIRX - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Viracta Therapeutics|VIRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Viracta Therapeutics Inc.|VIRX - Aggregate Debt Obligations|Debt to Book Value Viracta Therapeutics|VIRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Viracta Therapeutics|Quick Liquidity Indicator viracta.com
- net income and valuation ratios data:
VIRX - Net Profit
Fundamental company valuation:Viracta Therapeutics
Finished products of Viracta Therapeutics Inc.

This indicator measures financial leverage by comparing total liabilities to equity to assess the business's dependence on borrowed capital. By analyzing the total debt-to-equity ratio, an investor determines the stability of Viracta Therapeutics (VIRX), where the transparency of its targeted therapy strategy and proficient dialogue with the FDA minimize the risks of over-leverage during the scaling of development.

Competitor analysis for Viracta Therapeutics

ONC (BeiGene) - Total Debt to Capital|Total Debt to Equity Ratio Halozyme Therapeutics, Inc. (HALO)|Total Debt to Capital RVMD|Total Debt to Capital Ascentage Pharma Corp (AAPG)|Debt to Equity CG Oncology, Inc. CGON|URGN: Debt to Equity Ratio|Bicara Therapeutics - Total Debt to Capital|Personalis Inc (PSNL) - Total Debt to Equity Ratio|ERAS: Total Debt to Capital|Debt to Capital Delcath Corp (DCTH)|Debt to Equity Y-mAbs Therapeutics|AURA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Total Debt to Equity Ratio|CTOR: Total Debt to Equity Ratio|HURA - Total Debt to Capital|Protara Therapeutics, Inc. (TARA) - Debt to Equity|Fate Therapeutics Inc - All Debt to Shareholders' Equity Ratio|WHWK (Aadi Bioscience, Inc.) - Total Debt to Capital|Debt to Capital TScan TCRX|Total Debt to Equity Ratio CSBR (Champions Oncology)|Debt to Equity XBIT (xbiotech.com)|Total Debt to Capital CVM (CEL-SCI)|Total Debt to Capital Coefficient OS Therapies Inc. (OSTX)|RADX - Debt to Equity|All Debt to Shareholders' Equity Ratio ARTV (Artiva Biotherapeutics, Inc.)|ANL: Total Debt to Capital|verupharma.com (VERU) - Total Debt to Capital|TPST (Tempest Therapeutics, Inc.) - Total Debt to Capital|Total Debt to Equity Ratio Xilio (XLO)|Total Debt to Equity Ratio RENB (Renovaro Inc.)|Aggregate Debt to Capital MURA|Total Debt to Capital KAPA (Kairos Pharma)|Total Debt to Capital OnKure Therapeutics, Inc. OKUR|GDTC: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Total Debt to Equity Ratio|THAR: Aggregate Debt to Capital|ADVB (Advanced Biomed Inc.) - Total Debt to Capital|GNPX: All Debt to Shareholders' Equity Ratio|Total Debt to Capital CLDI|SBFM - Debt to Capital|Debt to Equity Xenetic Biosciences, Inc. XBIO|All Debt to Shareholders' Equity Ratio SLRX|Purple Biotech - Total Debt to Capital|AONC - Total Debt to Capital|BeiGene (BGNE) - Debt to Equity|Aggregate Debt to Equity CKPT (Checkpoint Therapeutics Inc.)|ELEV (Elevation Oncology, Inc.) - Total Debt to Capital|Debt to Capital iCAD Corp ICAD|Total Debt to Equity Ratio IKNA (Ikena Oncology, Inc.)|Total Debt to Capital notablelabs.com (NTBL)|MorphoSys - Total Debt to Equity Ratio|Aggregate Debt to Capital NAYA (NAYA Biosciences Inc)|Ascentage Pharma Group Ltd - Total Debt to Capital